Literature DB >> 1588423

Hearing preservation in acoustic neurinoma surgery.

G Fischer1, C Fischer, J Rémond.   

Abstract

The authors have reviewed hearing results obtained in 99 patients operated on via the suboccipital approach for acoustic neurinoma, who were not deaf prior to surgery (pure tone average less than 70 dB). Tumor size was less than 10 mm in four cases, 10 to 19 mm in 26 cases, 20 to 29 mm in 39 cases, and 30 mm or greater in 30 cases. Removal was macroscopically complete in 92 cases and incomplete in seven, including four cases with bilateral acoustic neurofibromatosis. Hearing was preserved in 29 patients (29.3%), of whom 23 had neurinomas smaller than 30 mm and six had tumors exceeding 30 mm in size. Postoperative hearing was good in eight cases (four with neurinomas less than 20 mm and four with neurinomas greater than 20 mm), serviceable in four cases (three with neurinomas less than 20 mm and one with a tumor greater than 30 mm), and poor in 17 cases (eight with neurinomas less than 20 mm and nine with tumors greater than 20 mm). Fifty-seven patients underwent intraoperative brain-stem auditory evoked potential monitoring: the rate of hearing preservation was found to be higher in this group than in the 42 without monitoring (p less than 0.05). A statistical study using stepwise regression analysis showed that the two preoperative factors most significantly associated with postoperative hearing preservation are a good auditory level for low frequencies measured by pure tone audiometry and a small-sized tumor. Overall results indicate that, even if hearing is more easily preserved when the neurinoma is small and the preoperative auditory condition is good, the surgeon should try to save hearing in all patients who have preserved hearing before surgery.

Entities:  

Mesh:

Year:  1992        PMID: 1588423     DOI: 10.3171/jns.1992.76.6.0910

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  20 in total

1.  Issues in the optimal selection of a cranial nerve monitoring system.

Authors:  S H Selesnick; D F Goldsmith
Journal:  Skull Base Surg       Date:  1993

2.  Continuous retrograde monitoring of the facial nerve: preliminary experience during acoustic neuroma surgery.

Authors:  V Colletti; F G Fiorino
Journal:  Skull Base Surg       Date:  1996

3.  Advantages of a new, atraumatic, self-retaining electrode for direct cochlear nerve monitoring.

Authors:  M J Ruckenstein; R A Cueva; G R Prioleau
Journal:  Skull Base Surg       Date:  1997

4.  The Changing Paradigm for the Surgical Treatment of Large Vestibular Schwannomas.

Authors:  Roy Thomas Daniel; Constantin Tuleasca; Alda Rocca; Mercy George; Etienne Pralong; Luis Schiappacasse; Michele Zeverino; Raphael Maire; Mahmoud Messerer; Marc Levivier
Journal:  J Neurol Surg B Skull Base       Date:  2018-08-23

5.  Factors influencing hearing preservation in acoustic tumor surgery.

Authors:  P Rastogi; A T Cacace; T J Lovely
Journal:  Skull Base Surg       Date:  1995

6.  Iatrogenic impairment of hearing during surgery for acoustic neuroma.

Authors:  V Colletti; F G Fiorino; L Sacchetto
Journal:  Skull Base Surg       Date:  1996

7.  Influence of blood supply, thermal and mechanical traumata on hearing function in an animal model.

Authors:  V Braun; H P Richter
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

8.  Preserving hearing in acoustic neuroma removal.

Authors:  J P Johnson; W A King; J C Andrews; D P Becker; R F Canalis
Journal:  West J Med       Date:  1993-07

9.  Evaluation of variation in the course of the facial nerve, nerve adhesion to tumors, and postoperative facial palsy in acoustic neuroma.

Authors:  Tetsuro Sameshima; Akio Morita; Rokuya Tanikawa; Takanori Fukushima; Allan H Friedman; Francesco Zenga; Alessandro Ducati; Luciano Mastronardi
Journal:  J Neurol Surg B Skull Base       Date:  2012-11-26

Review 10.  [Cerebellopontine angle surgery. Part 2: Specific remarks].

Authors:  B Schaller
Journal:  HNO       Date:  2003-03-28       Impact factor: 1.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.